EMA's PIP class waiver revisions are scientifically sound but may pose legal/ethical issues for companies
This article was originally published in SRA
Executive Summary
The European Medicines Agency's revision of its list of class waivers for pediatric investigation plans (PIPs)may result in legal or ethical challenges for pharmaceutical companies in cases where pediatric trials are requested for diseases with low prevalence in children, according to a legal expert1.